Renaissance Technologies
ESLA icon

Renaissance Technologies’s Estrella Immunopharma ESLA Stock Holding History

Renaissance Technologies’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.7K Sell
39,100
-23,695
-38% -$31K ﹤0.01% 3062
2026
Q1 		$66.6K Sell
62,795
-59,673
-49% -$68.6K ﹤0.01% 3081
2025
Q4 		$191K Buy
122,468
+111,779
+1,046% +$212K ﹤0.01% 2895
2025
Q3 		$12.3K Buy
+10,689
New +$10.3K ﹤0.01% 3446

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's ESLA Position: Q2 2026 in Review

Renaissance Technologies reduced its Estrella Immunopharma (ESLA) stake by 38% in Q2 2026, selling an estimated $31K and leaving 39,100 shares worth $40.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3062.

Renaissance Technologies first reported a position in ESLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $191K in Q4 2025. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Renaissance Technologies held 39,100 shares of Estrella Immunopharma worth $40.7K as of Q2 2026.
  • Renaissance Technologies sold 23,695 Estrella Immunopharma shares in Q2 2026, an estimated $31K.
  • Estrella Immunopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3062 holding.
  • Renaissance Technologies first reported a position in Estrella Immunopharma in Q3 2025 and has held it in 4 quarters since.
  • Renaissance Technologies's Estrella Immunopharma position peaked at $191K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.